Research Fellows Directory
Professor Wilhelm Schwaeble
University of Leicester
The award holder has established a research programme studying the organisation of a blood resident defence system of the innate immune system that under disease promoting circumstances can contribute to devastating inflammatory and life-threatening disease conditions.
The award holder established two independent therapeutic programmes with an industrial collaborator that has led to a powerful patent portfolio and the development of two clinical candidate inhibitors of which one is already in stage 3 of clinical trials, while the other one successfully passed the toxicology and efficacy studies at clinical trial stage 1.
Scientific publications: So far, the PI and his team published 86 original scientific papers on this technology in high ranking international journals, including Nature, PNAS, FASEB J., J. of Clinical Investigation, J. Immunol. etc….
Public engagement: So far, over 5600 articles, press releases and comments have been published on this technology in non-scientific press articles in national and newspapers and magazines.
Economic impact: The market for the treatment of microangiopathies, including Thrombotic Thrombocytopenic Purpura (TTP), atypical Haemolytic Syndrome (aHUS) and stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is estimated to be in excess of 2 Billion Dollars. Once approved for the treatment of the above listed rare disease conditions, further clinical trial applications could open up much wider market opportunities.
(see http://www.prnewswire.com/news-releases/omeros-corporation-confirms-oms721-phase-3-development-plan-with-european-medicines-agency-300305558.html )